Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:ATCCode |
gptkb:P01BF01
|
| gptkbp:brand |
gptkb:Coartem
gptkb:Riamet |
| gptkbp:CASNumber |
82186-77-4
|
| gptkbp:combines |
gptkb:artemether
|
| gptkbp:contraindication |
severe renal impairment
severe liver impairment hypersensitivity to lumefantrine |
| gptkbp:developedBy |
gptkb:China
|
| gptkbp:discoveredIn |
1970s
|
| gptkbp:drugClass |
gptkb:arylaminoalcohol
|
| gptkbp:eliminationHalfLife |
3–6 days
|
| gptkbp:excretion |
feces
|
| gptkbp:hasMolecularFormula |
C30H32Cl3NO
|
| https://www.w3.org/2000/01/rdf-schema#label |
lumefantrine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits hemozoin formation
|
| gptkbp:meltingPoint |
130–132 °C
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
sleep disorders
dizziness headache loss of appetite |
| gptkbp:usedFor |
treatment of malaria
|
| gptkbp:WHOModelListOfEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:artemether
|
| gptkbp:bfsLayer |
6
|